XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.09

-0.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (8422)	1/22/1999 7:59:00 PM
From: Robert S.	Read Replies (2) of 17367

Thanks, Cacaito, for your informative post. While your proposed scenario is logical, one can not rule out that the trial extension results from the exhibited therapeutic efficacy being marginal. Orphan Drug Status, fast-track designation, trial extension: in toto, George considers the above to be good news; do you? I have to comment on your belittling studies that don't support your views. You were the one who introduced the ABTI trial without caveats. You also demeaned the Lutsar study but have you ever pointed out the flaws of trials that presented BPI in a positive light? Those rose colored glasses are blurring your vision. Glad to see that you too have found value in abstract reviews. My opinions only.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next